Lisdexamfetamine dimesylate (Vyvanse) has been approved by the United States Food and Drug Administration to treat adults with binge-eating disorder.
It’s the first drug sanctioned in the United States to treat the disorder, the agency said in a news release. Lisdexamfetamine dimesylate was first approved in 2007 to treat attention-deficit/hyperactivity disorder for those aged six years and older.
The drug’s safety and effectiveness in treating binge-eating disorder were evaluated in clinical studies involving 724 people. Compared to participants taking a placebo, those taking lisdexamfetamine dimesylate experienced a decrease in the number of binge eating days per week and reported fewer obsessive-compulsive binge eating behaviors.
A central nervous system stimulant, lisdexamfetamine dimesylate could cause serious complications, including stroke and heart attack. It also could cause sudden death among users with heart problems, said the FDA.
Less serious side effects could include dry mouth, insomnia, increased heart rate, constipation, anxiety, and feeling jittery.
The drug is marketed by Shire U.S., based in Wayne, Pa.
This article originally appeared on Psychiatry Advisor